Recruiting Epilepsy Studies in Palo Alto
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy....
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy....
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures...
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilate...
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE)....
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001...
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation ...
About Epilepsy Clinical Trials in Palo Alto
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It affects about 50 million people worldwide. Treatment includes antiseizure medications, surgery, and neurostimulation devices.
There are currently 7 epilepsy clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 1,008 participants. Research is being sponsored by Biohaven Therapeutics Ltd., SK Life Science, Inc., Neurona Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Epilepsy Clinical Trials in Palo Alto — FAQ
Are there epilepsy clinical trials in Palo Alto?
Yes, there are 7 epilepsy clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What epilepsy treatments are being tested?
The 7 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for epilepsy.
Data updated March 2, 2026 from ClinicalTrials.gov